The Food and Drug Administration granted accelerated approval for Clovis Oncology Inc.'s (Nasdaq: CLVS) new drug application for rucaparib sending the stock price soaring $4.93 to close at $23.03.
FDA grants fast track to Clovis Oncology
August 23, 2016 at 19:32 PM EDT